Summary: The World Health Organization (WHO) has awarded prequalification to Mosquirix, GSK’s malaria vaccine. This is…
Companies
-
-
Bristol Myers SquibbU.S FDA
Bristol Myers Squibb Notches another FDA Approval for Sotyktu™ (Deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
by adminHighlights: Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is…
-
Boehringer IngelheimU.S FDA
Boehringer’s Spevigo (spesolimab) Bags First FDA Approval for Rare Skin Disease, for Generalized Pustular Psoriasis (GPP)
by adminSynopsis: German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy…
-
Sanofi Inc.U.S FDA
XenpozymeTM (Olipudase alfa-rpcp) Approved by FDA as First Disease-Specific Treatment for Acid Sphingomyelinase Deficiency, a Rare Genetic Disease to Sanofi
by adminSummary: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) Xenpozyme is the first approved medication…
-
AstraZenecaU.S FDA
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
by adminSynopsis: Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of…
-
Marius PharmaceuticalsU.S FDA
Marius Pharmaceuticals Receives FDA Approval of KYZATREX™, an Oral Testosterone Replacement Therapy
by adminSummary : Marius Pharmaceuticals, a patient-centric healthcare company, today announced the approval of KYZATREX™ (testosterone…
-
AstraZenecaMerger / Acquisition
AstraZeneca to Acquire TeneoTwo and its Clinical-stage T-cell Engager TNB-486
by adminSummary : AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I…
-
BayerMerger / Acquisition
Bayer to Sell Men’s Health Product Nebido™ to Grünenthal for 500 Million Euro.
by adminSummary : Bayer and Grünenthal have entered into a definitive agreement regarding the sale of…
-
Summary : GSK plc announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra…
-
Bristol Myers SquibbU.S FDA
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi®(lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
by adminSynopsis: In the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the…
Newer Posts